Nikhilesh N Singh

Learn More
OBJECTIVES Buffered low-dose sublingual transmucosal zolpidem lozenge hemitartrate (ST zolpidem) is being developed for the treatment of middle-of-the-night insomnia. The objective of this double-blind placebo-controlled cross-over study (n = 24) was to evaluate the pharmacokinetics (PK) and daytime-sedative profile of 1.0, 1.75, and 3.5 mg dose of the(More)
OBJECTIVE Evaluate potential gender effects on efficacy and safety of a buffered zolpidem sublingual tablet (ZST) formulation. METHODS Post hoc analysis of the pivotal sleep laboratory and outpatient studies, per gender. RESULTS In the sleep laboratory study, polysomnography-derived latency to persistent sleep after middle-of-the-night was significantly(More)
  • 1